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Background: We investigated prostate involvement during sexually transmitted infections by 
measuring serum prostate specific antigen (PSA) as a marker of prostate infection, inflammation, 
and/or cell damage in young, male U.S. military members. 
Methods: We measured PSA before and during infection for 299 chlamydia, 112 gonorrhea, and 
59 non-chlamydial, non-gonococcal urethritis (NCNGU) cases, and 256 controls.  
Results: Chlamydia and gonorrhea, but not NCNGU, cases were more likely to have a large rise 
(≥40%) in PSA than controls (33.6%, 19.1%, and 8.2% versus 8.8%, p<0.0001, 0.021, and 0.92, 
respectively). 
Conclusion: Chlamydia and gonorrhea may infect the prostate of some infected men. 
 
 
Key words: Sexually transmitted infections; chlamydia; gonorrhea; non-chlamydial, non-
gonococcal urethritis; prostate specific antigen; prostate cancer. 
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INTRODUCTION 
Despite ongoing interest in the role of exudative sexually transmitted infections (STIs; 
i.e., those that cause an inflammatory discharge) in prostate carcinogenesis (Sutcliffe, 2010), few 
studies have examined the likelihood of prostate involvement during infection, particularly in the 
current antibiotic era (Sutcliffe & Platz, 2007). We previously investigated this question by 
measuring serum prostate specific antigen (PSA) as a marker of prostate infection, inflammation, 
and/or cell damage in a small study of young, African-American STI patients (Sutcliffe et al, 
2006). We used PSA as a marker because it rises in men with acute bacterial prostatitis and 
asymptomatic histologic prostate inflammation (Sindhwani & Wilson, 2005). In our previous 
study, we found that men with exudative STIs were more likely to have a large rise (≥40%) in 
PSA during infection than controls, suggesting that prostate infection occurred in some infected 
men. To investigate the reproducibility of these findings and determine which STIs predict PSA 
elevation, we have now conducted a considerably larger study among U.S. military members 
with stored serum in the Department of Defense serum repository (DoDSR).  
 
METHODS  
Study population and design 
The DoDSR contains serum remaining from human immunodeficiency virus type 1 
(HIV-1) screening during pre-induction, at routine periodic intervals (every 2-5 years), before 
and after major overseas deployments, for clinical indications, and as part of standard clinical 
STI work-up. Specimens are linked to demographic information, service-related activity, and 
reportable (e.g., genital, chlamydial infection; gonorrhea; and non-chlamydial, non-gonococcal 
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urethritis (NCNGU)) and non-reportable medical diagnoses (Rubertone & Brundage, 2002; 
Silverberg et al, 2003).  
Men eligible for the present study were those who were <25 years of age as of 1995; 
HIV-1-negative; on continuous active duty from 1995-2006; and had several archived specimens 
in the DoDSR (n=75,387). We defined STI cases as men with a laboratory-confirmed diagnosis 
of chlamydia (ICD-9-CM code 099.41), gonorrhea (098), or NCNGU (099.40) in 2001-2003. 
Diagnoses were confirmed according to military guidelines; NCNGU required specific exclusion 
of chlamydia and gonorrhea (July, 1998). We defined controls as men with no STI or infectious 
mononucleosis diagnoses in their medical record up to 2006. Exclusion of mononucleosis 
diagnoses was needed for a separate investigation. Controls were frequency-matched to the 
entire case group by race. 
For each case, we selected two specimens from the DoDSR, one collected ±7 days of the 
case diagnosis (acute), and the first specimen collected >3 weeks before their acute specimen to 
account for the maximum typical incubation period of chlamydia and gonorrhea ((Hook & 
Handsfield, 2008; Stamm, 2008), pre-acute, range: 22 days-4 years before diagnosis). If a case 
had ≥2 diagnoses, only one was selected. Diagnoses without a specimen collected ±7 days were 
excluded. These criteria resulted in a sample size of 299 chlamydia, 112 gonorrhea, and 59 
NCNGU cases. Two specimens were also selected for each control, one collected from 2001-
2003 (“acute”) and the first specimen collected >3 weeks before their acute specimen (“pre-
acute”). If ≥2 “acute” specimens were available, one was randomly selected. Of the 68,584 
eligible controls, we selected 256 based on power considerations and available resources.  
This study was approved by the Walter Reed Army Institute of Research and Johns 
Hopkins. All data/specimens were anonymized before release from the DoDSR.  
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PSA measurement 
As participants were younger than the age range for routine prostate cancer screening, 
PSA was not available in their medical records. Therefore, we measured total PSA for all 
participants using the Access Hybritech assay (Beckman Coulter, Brea, CA). Specimens from 
the same individual were tested adjacent to one another in random within-person order. We 
determined assay reproducibility by testing 25 blinded quality control pairs from the DoDSR 
(coefficient of variation=12.4% and 6.9% after excluding one discrepant pair). Total PSA has 
been found to be relatively stable for 2-20 years at -20°C (Ulmert et al, 2006; Woodrum & York, 
1998), close to the storage temperature in the DoDSR (-30°C). 
Statistical analysis 
We initially explored PSA change between the pre-acute and acute specimens by 
comparing mean pre-acute and acute PSA for cases and controls. Values were adjusted for race 
to account for frequency-matching. We further explored PSA change by comparing race-adjusted 
categories of absolute and relative percent change. As in our previous analysis (Sutcliffe et al, 
2006), case and control distributions diverged at a 40-49% PSA rise; therefore, we used a ≥40% 
change to define a large rise.  
 
RESULTS 
We identified 299 cases of chlamydia, 112 of gonorrhea, and 59 of NCNGU, and selected 
256 controls for comparison. Compared to controls, cases were slightly younger; gonorrhea cases 
were more likely to be African-American; and all cases were more likely to be unmarried, 
enlisted, and to have had their blood drawn for clinical indications (Table 1). Cases also had a 
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greater number of blood draws, and a correspondingly shorter time between draws, particularly 
between their pre-acute and acute specimens. 
In general, STI cases had a higher mean pre-acute PSA than controls (p=0.0023, Table 2). 
Comparing pre-acute and acute specimens, chlamydia cases had a significantly greater mean 
change in PSA between specimens than controls, and were more likely to have a large rise in 
PSA at the time of their acute specimen, as defined by both absolute and relative change. For 
gonorrhea, although cases did not have a significantly greater mean change in PSA than controls, 
they were more likely to have both a large absolute and relative rise. The magnitude of this 
difference was, however, smaller than for chlamydia (p=0.0005). NCNGU cases were no more 
likely to have a large PSA rise than controls. No changes were observed after adjustment for age, 
calendar year of the pre-acute specimen, time between specimens, and pre-acute PSA. Only one 
of the four cases with recorded prostate symptoms (ICD-9-CM code 601) at the time of their STI 
diagnosis had a large PSA rise.  
As men were not necessarily tested for STIs at the time of their pre-acute specimen, we 
repeated the analyses restricted to men with ≥1 year between their pre-acute and acute specimens 
to remove men more likely to have been infected with their subsequently diagnosed acute STI at 
the time of their pre-acute specimen; in general, similar results were obtained. We also 
investigated the influence of additional diagnosed or undiagnosed STIs on the results by 
excluding: 1) men with additional infectious or genitourinary diagnoses immediately before their 
pre-acute specimen or between specimens; 2) cases with clinical or other suspicion of HIV/STIs 
as their reason for blood draw for their pre-acute specimen, and controls with these reasons for 
either specimen; 3) men with small breaks (<60 days) in their active duty status or deployed 
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between specimens; and 4) higher rank officers who may have greater access to non-military 
health care. All sensitivity analyses yielded similar results as the main analyses (data not shown). 
 
DISCUSSION 
In this large study of U.S. military members, men with exudative STIs were more likely 
to have a large PSA rise during infection than controls, similar to findings from our previous 
smaller study of STI patients (Sutcliffe et al, 2006). This rise was observed for chlamydia and 
gonorrhea, but not for NCNGU. Although cases were also more likely to have higher pre-acute 
PSA, this difference should not have influenced inferences for PSA change because similar 
findings were observed for absolute and relative change, only the latter of which varies 
depending on the pre-acute value. 
While all STIs had the potential for prostate involvement (Sutcliffe & Platz, 2007; 
Sutcliffe & Platz, 2008), chlamydia cases were most likely to have a large PSA rise, followed by 
gonorrhea cases, whereas NCNGU cases were no more likely to have a rise than controls. One 
possible reason for these differences may be likelihood of symptoms as a possible marker of 
duration of infection. We previously hypothesized that men with asymptomatic infections/non-
specific symptoms might be more likely to have prostate infection because of their likely lesser 
awareness of their STI and consequent delay seeking treatment. This delay might provide 
pathogens with greater opportunity to ascend to and infect the prostate, which we believe is a 
likely necessary first step for prostate carcinogenesis (Sutcliffe et al, 2006). This hypothesis is 
consistent with differences in the likelihood of symptoms for each STI. Approximately half of 
chlamydial infections are asymptomatic in men (Zimmerman et al, 1990), a large proportion of 
which are ultimately diagnosed in the military because of routine female screening, contact 
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tracing, and self-referral for risky behaviors; 1-49% of gonorrheal infections present without 
symptoms (Pedersen & Harrah, 1970; Turner et al, 2002); and a likely even smaller proportion 
of diagnosed NCNGU infections present without symptoms because NCNGU is typically only 
investigated in men with urethral symptoms. An alternative explanation for null NCNGU 
findings, but not for differences between chlamydia and gonorrhea, is that some NCNGU cases 
did not have an infectious etiology.  
Although we used PSA as a marker of prostate infection/inflammation/cell damage, PSA 
may also possibly rise as a result of a more generalized response to infection at other non-
prostate sites (e.g,. urethra), recent ejaculation (within one day), or digital rectal examination 
(DRE) (Tchetgen & Oesterling, 1997). We believe these possibilities are less likely because of 
null results for NCNGU, an STI defined by urethral inflammation; unchanged results after 
adjustment for sexual activity in our previous study (Sutcliffe et al, 2006); and the extreme rarity 
with which DREs are performed during routine STI work-up, especially in the military.  
In summary, young men with chlamydia and gonorrhea were more likely to have a large 
PSA rise during infection than controls. Future studies should investigate the specificity of this 
rise to prostate infection, as well as the long-term effects of infections on PSA and, by possible 
extension, the prostate environment. 
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Mean Age (years)c 29.9 29.2 29.0 29.1 <0.0001 (<0.0001) 
Race/ethnicity (%):d      
African-American 55.1 54.2 79.5 52.5  
Caucasian-American 36.3 36.1 16.1 35.6 0.0007 (0.27) 
Other 8.6 9.7 4.4 11.9  
Marital status (%):c      
Married 79.3 60.7 63.5 73.4 
<0.0001 (<0.0001) 
Other 20.7 39.3 36.5 26.6 
Military grade (%):c      
Enlisted 91.1 96.2 97.3 99.0 
0.011 (0.0012) 
Officer 8.9 3.8 2.7 1.0 
Reason for blood draw (%):c      
Routinee 69.6 22.3 25.0 17.6  
Clinically indicated/Part of an STI visitf 1.9 34.2 48.7 70.4 <0.0001 (<0.0001) 
Other/unknown 28.5 43.5 26.4 12.0  
Mean number of blood draws for HIV-1 
testing from Jan. 1, 1995 to Dec. 31, 2006 9.9 12.0 11.3 13.4 <0.0001 (<0.0001) 
Mean time between pre-acute and acute 
specimens (months) 16.8 11.9 12.0 10.7 <0.0001 (<0.0001) 
NCNGU = non-chlamydial, non-gonococcal urethritis 
a
  Values for cases and controls were calculated by linear regression adjusting for race (African-American, non-African-American), except for values for 
the race variable. 
b
 P-values were calculated by linear regression for continuous or binary variables, and by generalized logit regression for categorical variables. All 
models were adjusted for race (African-American, non-African-American). P-values reflect a test of independence across all groups. Values in 
parentheses compare all cases to controls. 
c
 At the time of blood draw of the acute specimen. 
d
 Cases were frequency-matched to controls by race/ethnicity. 
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e
 Indicates blood drawn for routine and pre- and post-deployment human immunodeficiency virus type 1 (HIV-1) tests, as well as HIV-1 tests 
performed as part of specialized physical examinations (e.g., for flight school). 
f
 Indicates blood drawn for self or clinical suspicion of HIV-1 or STIs, as well as from hospitalized patients or those visiting emergency rooms for 





Table 2:  Pre-acute and acute serum total prostate specific antigen (PSA) concentration for 470 young, male sexually transmitted infection 





 Gonorrhea cases 
(n=112) 
 NCNGU cases  
(n=59) 
 
PSA (ng/mL) Pre-acute Acute Pre-acute Acute p-valuea Pre-acute Acute p-valuea Pre-acute Acute p-valuea 
Geometric meanb  0.55 0.56 0.62 0.82 <0.0001 0.66 0.70 0.47 0.63 0.64 0.84 
Meanb 0.64 0.65 0.86 1.11 0.0078 0.80 0.93 0.32 0.70 0.82 0.33 
Rangec 0.38-0.76 0.38-0.80 0.43-0.87 0.52-1.33  0.44-0.98 0.44-1.04  0.48-0.82 0.46-0.86  
Distribution of absolute change in serum total PSA (%)b 
≤0.00 ng/mL 52.1 36.2  45.1  48.8  
0.01-0.09 ng/mL 24.7 19.8  31.1  30.6  
0.10-0.19 ng/mL 15.1 9.0  4.0  10.5  
0.20-0.29 ng/mL 2.8 7.4 <0.0001 6.1 0.0023 3.5 0.57 
0.30-0.39 ng/mL 2.1 5.5  1.5  1.9  
0.40-0.49 ng/mL 1.6 2.4  1.5  0.1  
≥0.50 ng/mL 1.6 19.7  10.6  4.6  
Distribution of relative percent change in serum total PSA (%)b 
≤0%  52.1 36.2  45.1  48.8  
0.1-9% 11.7 12.7  21.7  12.3  
10-19% 12.8 7.9  10.0  18.5  
20-29% 10.1 5.6 <0.0001 1.9 0.0044 11.8 0.38 
30-39% 4.5 3.9  2.2  0.3  
40-49% 1.8 5.6  3.8  3.3  
≥50% 7.0 28.0  15.3  5.0  
Large relative rise in PSA (%)b 
≥40% 8.8 33.6 <0.0001 19.1 0.021 8.2 0.92 
NCNGU = non-chlamydial, non-gonococcal urethritis 
a
 P-values were calculated by linear regression with robust variance estimation for continuous variables, logistic regression for categorical variables and 
linear regression for binary variables. All models were adjusted for race (African-American, non-African-American). 
b
 Values were calculated by linear regression adjusting for race (African-American, non-African-American). 
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c
 Not adjusted for race. 
 
